OncoRNA
OncoRNA develops personalized mRNA-based cancer immunotherapy vaccines that direct patients' immune systems against their tumors.
OncoRNA is developing next-generation personalized cancer immunotherapy using mRNA vaccine technology. The company was selected by the European Commission for the IPCEI Med4Cure project and aims to deliver personalized cancer immunotherapy batches within 3 weeks using synthetic DNA production methods.
Key People
Christophe Van Huffel - Co-founder